United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$355.59 USD
+2.59 (0.73%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $355.80 +0.21 (0.06%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth F Momentum D VGM
Brokerage Reports
0 items in cart
United Therapeutics Corporation [UTHR]
Reports for Purchase
Showing records 361 - 380 ( 611 total )
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
September and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
August and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Competitive Pressures Materialize; Expect Increased Clarity on Additional Attacks in Coming Quarters
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q2 Financials Strong Beat and Long-Term Growth from New Products and Expansion into New Indications; Reiterate OUTPERFORM and $229 PT.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
The Week Ahead in Life Sciences: Upcoming Events for the Week of July 25
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q2 Preview: We Believe Consensus Is Achievable;Reiterate OUTPERFORM and $229 Price Target.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q2 Preview: We Project Top- and Bottom-line Beat on Solid Product Sales; Reiterate OUTPERFORM and $229 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
UTHR v. World: Update on the Many Threads of IP Litigation
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Scales Are Tipping the Other Way; Downgrading to Neutral and Lowering PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
June and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
May and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q1 Revenues Choppy but Annual Growth Remains Intact; Late-Stage Pipeline Could Provide Future Revenue Growth
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q1 Preview: Consensus Revenue Slightly High but GAAP EPS Achievable In Our View
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L